about
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimatesQuality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer.Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.Implementation of a "real-world" learning health care system: Washington State's Comparative Effectiveness Research Translation Network (CERTAIN).Readmissions in the postoperative period following urinary diversionUser-centered design of quality of life reports for clinical care of patients with prostate cancer.Identification of underserved areas for urologic cancer care.Variations in reconstruction after radical cystectomyUse of radical cystectomy for patients with invasive bladder cancer.Outcomes in men denied access to a California public assistance program for prostate cancer.Hospital-level variation in the quality of urologic cancer surgery.Hospice use and high-intensity care in men dying of prostate cancer.Initial experience with laparoscopically assisted percutaneous cryotherapy of renal tumors.A national study of trauma level designation and renal trauma outcomes.Prostate cancer mortality following active surveillance versus immediate radical prostatectomy.Trends in followup imaging after adult pyeloplastyEffects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial.Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancerMortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis.Quality of care in bladder cancer: trends in urinary diversion following radical cystectomy.Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer.Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.Individualized estimates of overdiagnosis in screen-detected prostate cancer.Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder cancer.Readability of urologic pathology reports: the need for patient-centered approaches.The role of serum testosterone testing: routine hormone analysis is an essential part of the initial screening of men with erectile dysfunction.Perinephric fat thickness is an independent predictor of operative complexity during robot-assisted partial nephrectomy.Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder.Rising PSA during Testosterone Replacement Therapy.Use and outcomes of extended antibiotic prophylaxis in urological cancer surgery.Adoption of laparoscopic radical nephrectomy in the state of Washington.Urinary and sexual outcomes in long-term (5+ years) prostate cancer disease free survivors after radical prostatectomy.Downstream complications following urinary diversion.Obesity and outcome following renal transplantation.Burden and timing of venothrombolic events in patients younger than 65 years undergoing radical cystectomy for bladder cancer.Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer.Improved continence in patients with neurogenic sphincteric incompetence with combination tubularized posterior urethroplasty and fascial wrap: the lengthening, narrowing and tightening procedure.Erectile aid use by men treated for localized prostate cancer.Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.Obesity and renal transplantation: is bariatric surgery the answer?
P50
Q28251617-49B0A8FE-E2A2-4C96-B342-2448C7E8FC29Q33845220-9FD0400F-18C7-450C-B4D7-F79256B469DDQ34326169-391657F5-2992-4D59-8172-B176BABF4408Q34418333-B516EAAC-62CB-489E-BF4A-20CC5E6FD842Q34508133-017223E8-1A76-4D1A-8D8F-3315106CBF96Q34541445-AFD4CD7C-D39A-40CA-AD48-235F63440748Q34541452-050C7BBF-0EC0-4814-8945-4C346F665DC7Q35622834-6220200C-6CBE-4A08-9BC3-A434CA68D7A6Q35632786-1DFED671-C904-4601-B448-8E2B82F480BAQ35676077-DCAF4870-619E-49CE-9BAD-C226D7B6A6C5Q35740209-D2ECD7F9-1F91-475E-A3D7-BCB2C311B359Q35777885-971BCF71-5E9E-4DE1-8375-7DC0DF32B093Q36135358-AF3BDEDD-3414-4D3F-A0E6-0904760D4882Q36296714-D7C49B4E-F171-400A-9156-74B6EC2EE218Q36706936-C205A4A4-42B3-4403-8832-A69E81807B16Q36839560-50420FAF-1AFB-49C3-AD53-A2604D33743DQ36953558-9BC99426-D1BD-439B-A661-A810F2361DD1Q37120159-719D14B9-E949-48D2-BD7D-72F9733AE0CEQ37125906-7FF99B3A-9D04-417E-93C1-096E9E5585ACQ37261045-F0D53FEB-E399-4840-BB13-6D621FBF161FQ37395746-54DED67E-C710-4751-A0E7-382ED49125C0Q37411206-81433FC6-9653-4088-B761-72BE85AA1905Q37634486-866B2A0E-E8AB-4F22-B137-062F910C7076Q38190219-BC495D83-9824-4DF7-953C-B32376C99BFAQ38213296-4B5E77B1-8B0D-4BF9-BA3F-9538F863262FQ39214484-7B8A2892-E3A8-4B7B-A2F3-151764C6FDB9Q39282735-859D60B6-3388-4924-9A46-5441B3687DA0Q39289774-8E176B3D-4FC9-4333-8236-8B1E669F81B0Q39769173-B4F8F4A3-7A1C-436A-B875-14BD461A2B34Q42225296-EA391501-5410-407D-BBC3-49860E1F70CCQ42635153-35E312B7-07CA-4B9A-9913-D3C1DDDB1AF9Q42676692-D1C2DDD2-A704-4859-903A-7CA27AFA4AE8Q43482325-EDDE91AF-E01A-4CF4-8468-C4DC9CB46FAFQ44433270-6DCCB9E6-7A7E-4C71-8E37-3B78F32FF9DDQ44546663-8357F769-B1F6-45AF-8156-D861ED7D5669Q44603939-8EFC3594-1F2A-45EB-A267-0CD57E0F37DAQ44730416-D6DB6C2E-960B-4A54-9F63-D10B3E940600Q44784365-10F2AC82-889A-4A22-B609-D5A45C9AE1DCQ44855302-F7F87030-A33C-44C8-ABE0-A2B449890165Q45937075-7F91980A-85CB-4C87-9CF3-8C8F9446E23C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John L Gore
@ast
John L Gore
@en
John L Gore
@es
John L Gore
@nl
John L Gore
@sl
type
label
John L Gore
@ast
John L Gore
@en
John L Gore
@es
John L Gore
@nl
John L Gore
@sl
prefLabel
John L Gore
@ast
John L Gore
@en
John L Gore
@es
John L Gore
@nl
John L Gore
@sl
P106
P21
P31
P496
0000-0002-2847-5062